In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease
CMPI 类似物在帕金森病优化斑马鱼模型中的体外药理学和体内神经保护作用
基本信息
- 批准号:10412533
- 负责人:
- 金额:$ 14.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-20 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffinityAgonistAmericanAnatomyAnimal ModelAnimalsAnti-Inflammatory AgentsAwardBehavioralBindingBiologicalBiomedical ResearchBrainCharacteristicsChemosensitizationClinicalCognitive deficitsCommunitiesDataDevelopmentDiseaseDisease ProgressionDopamineDrug ScreeningDrug TargetingEffectivenessElectrophysiology (science)EnsureFutureGoalsHumanImpaired cognitionIn VitroInterleukin-1 betaIsoxazolesKnowledgeLaboratoriesLeadLevodopaLewy BodiesLigandsMeasurableMeasuresMissionModelingMolecularMotorMotor ActivityMutation AnalysisNeurobehavioral ManifestationsNeuronsNeurotransmittersNicotinic ReceptorsOxidopamineParkinson DiseasePathologyPathway interactionsPatientsPharmaceutical PreparationsPharmacologyPhenotypeProductionPropertyReproducibilityResearchResearch Project GrantsResearch TrainingStudentsSymptomsTestingTexasTherapeuticTimeUnited States National Institutes of HealthUniversitiesZebrafishacetylcholine receptor agonistalpha synucleinanalogassociated symptomclinical developmentclinically relevantcostdisease phenotypedopaminergic neurondrug developmenteffective therapyexperimental studyhigh throughput screeningimprovedin vivoin vivo Modelin vivo evaluationinsightmotor symptomnovelnovel strategiesnovel therapeuticspharmacophorepositive allosteric modulatorpre-clinicalprogramsresponsescreeningsymptom treatmenttherapy outcomeundergraduate student
项目摘要
Parkinson’s Disease (PD) results from multiple underlying pathologies, including accumulation of a-synuclein-
containing Lewy bodies, loss of dopaminergic neurons, and perturbation of other neurotransmitter pathways.
While increasing dopamine production using the precursor L-DOAP seems effective at reducing PD symptoms
at first, the continuous decline in the number of dopaminergic neurons as PD progresses reduces the
effectiveness of L-DOPA, and additional therapy to control the PD's symptoms becomes necessary. The lack of
disease-modifying drugs that target PD's underlying pathologies and stop its progression represents a significant
gap in our knowledge and unmet clinical need. Therefore, this application aims to initiate early step experiments
in a continuum of research that is likely to lead to the development of clinically relevant positive allosteric
modulators (PAMs) of nicotinic acetylcholine receptors (nAChRs) which are known to have neuroprotective, anti-
inflammatory, and precognitive properties and thus hold promise for the development of drugs with disease-
modifying properties for PD.
In this proposal, we are taking advantage of a lead pharmacophore, CMPI, that we have identified as an
(α4)3(β2)2 nAChR-selective PAM and its analogs to develop selective nAChR PAMs and to provide proof-of-
concept evidence of their in vivo efficacy against PD. We propose the following specific aims: 1) Identification of
CMPI analogs with high potency, efficacy, and selectivity as (α4)3(β2)2 nAChR PAMs; 2A) Optimization of a
zebrafish model for in vivo Parkinson’s disease drug screening; and 2B) Assessment of nAChR PAMs effect on
behavioral, anatomical, and molecular measures of PD progression.
Upon accomplishing these specific aims, we expect that CMPI analogs that bind with high affinity and selectivity
to and potentiate agonist-induced responses of (α4)3(β2)2 nAChR will be identified. The anticipated results will
also provide in vivo evidence to support the pharmacological merit of α4β2 nAChR PAMs as a novel strategy to
slow the progression of motor and cognitive decline associated with PD. The proposed research project will also
optimize conditions for a reliable zebrafish PD-like phenotype animal model with measurable behavioral,
anatomical, and biological readouts suitable for high throughput screening of novel therapeutic compounds for
PD. This model will help reduce the time and cost of selecting lead compounds for future animal and human
studies and facilitate the development of novel therapeutics for the treatment of motor symptoms and cognitive
decline associated with Parkinson’s disease. Once such drugs become clinically relevant, progress will have
been made toward effective PD treatment and advancing the National Institutes of Health mission.
帕金森病(PD)由多种潜在病理引起,包括α-突触核蛋白的积累,
含有路易体、多巴胺能神经元的损失和其他神经递质通路的干扰。
虽然使用前体L-DOAP增加多巴胺的产生似乎对减少PD症状有效,
首先,随着PD的进展,多巴胺能神经元数量的持续下降减少了
L-DOPA的有效性,以及控制PD症状的额外治疗变得必要。缺乏
靶向PD的潜在病理并阻止其进展的疾病修饰药物代表了一种重要的
我们的知识差距和未满足的临床需求。因此,本申请旨在启动早期实验
在一个连续的研究,这可能导致临床相关的积极变构的发展,
烟碱乙酰胆碱受体(nAChR)的调节剂(PAM),其已知具有神经保护性、抗-
炎性和抗炎性,因此有望开发治疗疾病的药物-
改性PD的性能。
在这个提议中,我们利用了一个主要药效团CMPI,我们已经确定它是一个
(α4)3(β2)2 nAChR选择性PAM及其类似物,以开发选择性nAChR PAM并提供
概念证据表明它们对PD的体内功效。我们提出以下具体目标:1)确定
作为(α4)3(β2)2 nAChR PAM的具有高效力、功效和选择性的CMPI类似物; 2A)对CMPI类似物的优化,
用于体内帕金森氏病药物筛选的斑马鱼模型;和2B)nAChR PAM对帕金森氏病的作用的评估。
PD进展的行为、解剖和分子测量。
在实现这些特定目标后,我们期望以高亲和力和选择性结合的CMPI类似物
并增强激动剂诱导的(α4)3(β2)2 nAChR反应。预期结果将
还提供了体内证据,支持α4β2 nAChR PAM作为一种新策略的药理学价值,
减缓与PD相关的运动和认知衰退的进展。拟议的研究项目还将
优化具有可测量行为的可靠斑马鱼PD样表型动物模型的条件,
解剖学和生物学读数,适用于高通量筛选新的治疗化合物,
警局该模型将有助于减少未来动物和人类选择先导化合物的时间和成本
研究和促进新的治疗方法的发展,用于治疗运动症状和认知
与帕金森病相关的衰退。一旦这些药物成为临床相关的,进展将有
致力于有效的PD治疗和推进国立卫生研究院的使命。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ayman K. Hamouda其他文献
Examining the Structure of the Neuronal a4b2 nAChR Transmembrane Domain by Photoaffinity Labeling
- DOI:
10.1016/j.bpj.2008.12.775 - 发表时间:
2009-02-01 - 期刊:
- 影响因子:
- 作者:
Ayman K. Hamouda;S. Shaukat Husain;Michael P. Blanton;Jonathan B. Cohen - 通讯作者:
Jonathan B. Cohen
Photoaffinity Labeling the Agonist Binding Domain of α4β4 and α4β2 Neuronal Nicotinic Acetylcholine Receptors with [125I] Epibatidine and 5[125I]A-85380
用 [125I] Epibatidine 和 5[125I]A-85380 光亲和标记 α4β4 和 α4β2 神经元烟碱乙酰胆碱受体的激动剂结合域
- DOI:
- 发表时间:
2009 - 期刊:
- 影响因子:0
- 作者:
Ayman K. Hamouda;Xiaochun Jin;M. Sanghvi;Shouryadeep Srivastava;Akash;Pandhare;Phaneendra K. Duddempudi;J. Steinbach;M. P. Blanton - 通讯作者:
M. P. Blanton
Photoaffinity Labeling the Agonist Binding Sites of nAChRs with [<sup>3</sup>H]Epibatidine
- DOI:
10.1016/j.bpj.2008.12.773 - 发表时间:
2009-02-01 - 期刊:
- 影响因子:
- 作者:
Shouryadeep Srivastava;Ayman K. Hamouda;Mitesh Sanghvi;Akash Pandhare;Phaneendra K. Duddempudi;Sarah Hiyari;David C. Chiara;Jonathan B. Cohen;Michael P. Blanton - 通讯作者:
Michael P. Blanton
Pyrrolidinyl benzofurans and benzodioxanes: selective α4β2 nicotinic acetylcholine receptor ligands with different activity profiles at the two receptor stoichiometries.
吡咯烷基苯并呋喃和苯并二恶烷:选择性 α4β2 烟碱乙酰胆碱受体配体,在两种受体化学计量上具有不同的活性特征。
- DOI:
10.1016/j.bmcl.2022.128701 - 发表时间:
2022 - 期刊:
- 影响因子:2.7
- 作者:
Rebecca Appiani;M. Pallavicini;Ayman K. Hamouda;C. Bolchi - 通讯作者:
C. Bolchi
Examining the effect of a substituted carbamate positive allosteric modulator on the (α4)3(β2)2 and (α4)2(β2)3 nicotinic acetylcholine receptors
- DOI:
10.1016/j.bpj.2022.11.2157 - 发表时间:
2023-02-10 - 期刊:
- 影响因子:
- 作者:
Josue Gaona;Musharaf Mohiuddin;Ayman K. Hamouda - 通讯作者:
Ayman K. Hamouda
Ayman K. Hamouda的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ayman K. Hamouda', 18)}}的其他基金
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease
CMPI 类似物在帕金森病优化斑马鱼模型中的体外药理学和体内神经保护作用
- 批准号:
10624889 - 财政年份:2022
- 资助金额:
$ 14.7万 - 项目类别:
Neuronal nicotinic acetylcholine receptors (nAChRs)
神经元烟碱乙酰胆碱受体 (nAChR)
- 批准号:
9681760 - 财政年份:2018
- 资助金额:
$ 14.7万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 14.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 14.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 14.7万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 14.7万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 14.7万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 14.7万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 14.7万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 14.7万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 14.7万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 14.7万 - 项目类别: